Search Results - "Strong, Jodi"

The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit by Patel, Dhiren K., Strong, Jodi

“…Type 2 diabetes (T2D) is associated with an increased risk of macro- and microvascular complications, including cardiovascular disease (CVD), heart failure…”
Get full text

Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance by Jain, Akshay B, Ali, Amar, Gorgojo Martínez, Juan J, Hramiak, Irene, Kavia, Ketan, Madsbad, Sten, Potier, Louis, Prohaska, Ben D, Strong, Jodi L, Vilsbøll, Tina

“…Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an established treatment for patients with type 2 diabetes (T2D). Differences between GLP-1RAs in…”
Get more information

Initiative to Improve Evidence-Based Chronic Obstructive Pulmonary Disease Hospitalist Care Using a Novel On-Line Gamification Patient Simulation Tool: A Prospective Study by Strong, Jodi, Weems, Larry, Burgon, Trever, Branch, Jeremy, Martin, Jenny, Paculdo, David, Tamondong-Lachica, Diana, Cruz, Jamielyn, Peabody, John

“…Chronic obstructive pulmonary disease (COPD) remains a leading cause of morbidity and mortality. Much of the disease burden comes from exacerbations requiring…”
Get full text

ABC Goal Attainment in Type 2 Diabetes Mellitus Patients in US Primary Care by Bajaj, Harpreet S, Shahady, Edward J, Strong, Jodi L, Dex, Terry, Dalal, Mehul, Frimpter, Jeffrey, Zhou, Wei, Stewart, John

Get full text

Are there differences in the efficacy of once-weekly GLP-1RAs in patients with type 2 diabetes? by Strong, Jodi

“…ABSTRACT Several long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been developed for the treatment of people with type 2 diabetes (T2D)…”
Get full text

iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes by Hinnen, Debbie, Strong, Jodi

“…Patients with type 2 diabetes require treatment intensification to maintain glycemic control. Clinician reluctance, patient injection fears, hypoglycemia,…”
Get full text

Evolution and Revolution-Our Changing Relationship With Insulin by Anderson, John, Van Doorn, Mary, Strong, Jodi

“…Type 2 diabetes is a progressive condition with a complex pathophysiology. Over time, additional therapies are needed to maintain glycemic control. It is well…”
Get full text

Be Prepared, Not Scared: Making the Most of Mock Codes by Strong, Jodi

Get full text

Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes by Strong, Jodi, Kruger, Davida, Novak, Lucia

“…Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in…”
Get full text

Insulin glargine 300 U/mL versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real‐life clinical trial by Meneghini, Luigi, Blonde, Lawrence, Gill, Jasvinder, Dauchy, Arnaud, Bacevicius, Andrius, Strong, Jodi, Bailey, Timothy S.

“…Aim To report the effectiveness and safety of insulin glargine 300 U/mL (Gla‐300) versus standard‐of‐care basal insulin analogues (SOC‐BI) at 12 months in the…”
Get full text

Insulin Initiation and Titration in Patients With Type 2 Diabetes by Chun, Ji, Strong, Jodi, Urquhart, Scott

“…Insulin initiation and titration can be challenging for many primary care providers who are involved in the treatment of patients with type 2 diabetes. Despite…”
Get full text

Insulin glargine 300U/mL versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real‐life clinical trial by Meneghini, Luigi, Blonde, Lawrence, Gill, Jasvinder, Dauchy, Arnaud, Bacevicius, Andrius, Strong, Jodi, Bailey, Timothy S

“…AimTo report the effectiveness and safety of insulin glargine 300 U/mL (Gla‐300) versus standard‐of‐care basal insulin analogues (SOC‐BI) at 12 months in the…”
Get full text

1087-P: A Randomized Pragmatic Real-World Clinical Trial Comparing Insulin Glargine 300 U/mL (Gla-300) with Standard of Care First-Generation Basal Insulins (SoC-BIs) in Insulin-Naïve Patients with Type 2 Diabetes: Twelve-Month Analysis of the ACHIEVE Control Study by MENEGHINI, LUIGI, GILL, JASVINDER, DAUCHY, ARNAUD, BACEVICIUS, ANDRIUS, STRONG, JODI, BAILEY, TIMOTHY S.

“…ACHIEVE Control, a pragmatic randomized real-world clinical trial, prospectively compared the effectiveness and safety of Gla-300 vs. SoC-BIs (glargine 100…”
Get full text

How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice? by Tibaldi, Joseph, Mercado, Max E, Strong, Jodi

“…The efficacy and safety of the fixed-ratio combination of insulin degludec (degludec) and liraglutide (IDegLira) were confirmed in the DUAL clinical trial…”
Get full text

A Quality Collaboration in Heart Failure and Pneumonia Inpatient Care at Novant Health: Standardizing Hospitalist Practices to Improve Patient Care and System Performance by Weems, Larry, Strong, Jodi, Plummer, Dianne, Martin, Jenny, Zweng, Thomas N., Lindsay, Jeff, Paculdo, David, Tran, Mary, Peabody, John

“…Heart failure and pneumonia are among the most measured and expensive conditions to treat in the United States across all payer types and are top of mind for…”
Get full text

Real-world evidence in diabetes: relevance to clinical practice by Blonde, Lawrence, Bailey, Timothy, Strong, Jodi, Levin, Philip

“…Real-world studies may be distinguished from traditional randomized controlled trials (RCTs) based on the study population and the setting in which the…”
Get full text

Post Hoc Analysis Evaluating the Impact of Antihyperglycemic Background Therapies on Attainment of A1C Targets Without Hypoglycemia in the ACHIEVE Control Pragmatic, Real-Life Study by Bailey, Timothy S, Evenou, Pierre, Gill, Jasvinder, Berhanu, Paulos, Raymond, Romain, Strong, Jodi, Wright, Jr, Eugene E

“…ACHIEVE Control, a prospective, open-label, randomized, pragmatic, real-life study in insulin-naive people with type 2 diabetes (A1C 8.0-11.0%), demonstrated…”
Get full text

Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support Program by Goldman, Jennifer D., Gill, Jasvinder, Horn, Tony, Reid, Timothy, Strong, Jodi, Polonsky, William H.

“…Introduction Persistence with basal insulin therapy can be suboptimal, despite recent improvements in insulin formulations and delivery systems. Patient…”
Get full text

Construction of An Outpatient Erythrocytapheresis Program for Pediatric Patients with Sickle Cell Disease by Bryant, Paulette, Parmley, Richard, Bolen, Christine, Sunderland, Theresa, Johnson, Robert, Weisner, Jennifer, Nishioka, Karen, Roberts, Karen, Towell, Richard, Strong, Jodi P., Lockhart, Evelyn, Mogul, Mark

“…An Erythrocytapheresis program was started at our institution in October 2006 for pediatric patients with sickle cell anemia who suffered from stroke(n=4) or…”
Get full text